Sera Medicines

What Sera Medicines does

Sera Medicines is a privately held biologics-focused accelerator founded in 2023 and headquartered in Boston, Massachusetts. The company incubates next-generation protein therapeutics programs and, upon achieving key value inflections, enables progression toward and beyond the clinic via formation and financing of independent spinout companies. Its core technology centers on antibody engineering, bispecific antibody design, drug discovery, manufacturing, and clinical development capabilities applied to complex diseases with significant unmet medical needs. Sera's operating model is venture-style: programs are incubated in-house with a team spanning biology, chemistry, antibody engineering, drug discovery, manufacturing, clinical development, operations, and business development, then spun out as separate financed entities.

Sera's revenue model is not based on commercial product sales. Instead, the company generates value through the creation and financing of spinout companies, retaining equity and partnership interests in those entities. As examples: Tenet Medicines was acquired by Eliem Therapeutics with a concurrent $120M private placement; Navigator Medicines closed a $100M Series A; Slate Medicines launched with $130M Series A co-led by Forbion and Foresite Capital; and Memento Medicines launched with $93M Series A. The company is supported by RA Capital Management as its primary investor since founding, with additional financial and strategic partnerships including DartsBio Pharmaceuticals (in-licensing relationship for Slate's lead asset SLTE-1009).

The company's customer relationships are not transactional but partnership-based: it engages pharmaceutical development partners, in-licensing counterparties (e.g., DartsBio), and institutional investors across spinout financings. Sera's go-to-market is essentially enterprise/B2B deal-making with biopharma investors and developers rather than product distribution. With 11-50 employees and a small lease at 200 Berkeley Street in Boston, the company operates as a lean, specialized venture-creation platform, evolving its program portfolio across autoimmune, migraine/headache, and retinal disease indications.

Name

Sera Medicines

Legal name

Sera Medicines, LLC

Website

https://seramedicines.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Sera Medicines is a privately held Boston-based biologics accelerator founded in 2023 that incubates next-generation protein therapeutics and spins out financed companies (Tenet, Navigator, Slate, Memento) to advance antibody and bispecific programs in autoimmune, migraine, and retinal diseases.

Ownership category

akta.pro rank

Product category

Biologics Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

akta.pro secondary industry

Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Biologics drug development
• Protein therapeutics
• Antibody engineering
• Biotech accelerator
• Therapeutic spinouts

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Platform Licensing and Spinout Creation: Sera Medicines operates as an accelerator that incubates therapeutic programs and creates spinout companies. Revenue generation occurs through the formation and financing of spinout companies (Tenet Medicines, Navigator Medicines, Slate Medicines) which advance programs through clinical development and potential acquisition or partnership. The company was founded in 2023 and is in early-stage development phase.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Sera Medicines is a biologics-focused accelerator that incubates therapeutic programs and creates and finances spinout companies to advance next-generation protein therapeutics. Once an incubated program reaches a key value inflection, Sera enables rapid progression toward and beyond the clinic by forming and capitalizing independent spinouts such as Tenet Medicines, Navigator Medicines, Slate Medicines, and Memento Medicines, each focused on distinct therapeutic areas including autoimmune diseases, migraine/headache disorders, and retinal diseases.

Product overview

Sera Medicines is a biologics-focused accelerator advancing next-generation protein therapeutics to treat complex diseases with significant unmet medical needs. The company does not offer a unified product platform but rather incubates therapeutic programs and spins them out into independent companies. Its portfolio includes spinouts such as Tenet Medicines, Navigator Medicines, Slate Medicines, and Memento Medicines — each focused on distinct therapeutic areas including autoimmune diseases, migraine/headache disorders, and retinal diseases. Sera functions as an incubator and accelerator rather than a product company.

Differentiator

Problem solved

Functional benefit

Products and services

• Navigator Medicines (Spinout Program) Spinout company incubated by Sera Medicines advancing NAV-240, an anti-OX40L and anti-TNFα bispecific antibody therapeutic for autoimmune diseases, launched with $100 million Series A financing.
• Slate Medicines (Spinout Program) Spinout company incubated by Sera Medicines advancing anti-PACAP monoclonal antibody therapies, including SLTE-1009, for the prevention of migraine and other headache disorders, launched with $130 million Series A financing.
• Memento Medicines (Spinout Program) Spinout company incubated by Sera Medicines advancing a Tie2 agonist and VEGF inhibitor bispecific antibody therapy for retinal diseases, launched with $93 million Series A financing.
• Tenet Medicines (Spinout Program) Spinout company incubated by Sera Medicines focused on biologics, subsequently acquired by Eliem Therapeutics with a concurrent $120 million private placement.

Quantifiable outcome

• Successfully spun out multiple companies including Tenet Medicines (acquired by Eliem Therapeutics), Navigator Medicines ($100M Series A), and Slate Medicines ($130M Series A)

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• DartsBio Pharmaceuticals (Guangdong), Ltd.coreStrategic or Co-development Partner · 24 February 2026DartsBio Pharmaceuticals in-licensed its lead program SLTE-1009, a monoclonal antibody targeting PACAP, to Slate Medicines. SLTE-1009 is being advanced for the prevention of migraine and other headache disorders with Phase 1 clinical trials planned for mid-2026.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• PureTech Health: PureTech is a clinical-stage biotherapeutics company that develops and owns multiple therapeutic programs and subsidiaries (e.g., Gelesis, Karuna, Vor). Its model of holding equity in spun-out biotechs while providing R&D infrastructure closely mirrors Sera Medicines' accelerator structure.
• Medicxi: Medicxi is a biotech-focused investment firm that builds and funds multiple asset-centric companies from a shared operational platform. The "asset-centric" structure and approach to spinning out focused biotechs is highly comparable to Sera's per-program spinout approach.
• Roivant Sciences: Roivant operates a similar "Vants" model of incubating and spinning out subsidiary biotech companies across multiple therapeutic areas, retaining equity and operational oversight. Sera's spinout model is conceptually analogous — both create multiple clinical-stage biotechs from a parent platform.

Emerging players

• Compass Therapeutics: Compass Therapeutics is a clinical-stage oncology biologics company developing antibody therapeutics, including bispecifics. Sera's Principal Scientist Frano Irvine previously worked at Compass, evidencing talent overlap; Compass's bispecific antibody pipeline is comparable in modality to Sera's spinout programs.

Regional players

• Omega Therapeutics: Omega Therapeutics is a Boston-area clinical-stage biotechnology company developing programmable epigenetic medicines. While a single-asset company rather than an accelerator, it shares Sera's Boston biotech ecosystem, biologics focus, and RA Capital investor relationships.

Others

• Atlas Venture: Atlas Venture is a biotech-focused venture firm that builds new companies from academic science through a company-creation model. While a venture firm rather than an operating company, Atlas' pattern of forming biotechs with shared operational infrastructure parallels Sera's spinout model.
• Flagship Pioneering: Flagship Pioneering originates and funds multiple biotech ventures, several of which have hired from the same talent pool as Sera. While its portfolio spans diverse modalities, its company-creation approach is comparable in spirit to Sera's incubator model.

Broad incumbents

• BridgeBio Pharma: BridgeBio runs multiple therapeutic programs under a single umbrella, with a model of forming focused subsidiaries for individual assets. While broader than Sera's accelerator focus, the multi-program parallel-development structure is conceptually similar.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sera-medicines-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sera Medicines